637,528 Shares in Maze Therapeutics, Inc. (NASDAQ:MAZE) Bought by Harvard Management Co. Inc.

Key Points

• Harvard Management Co. Inc. has acquired a new position in Maze Therapeutics, Inc., purchasing 637,528 shares valued at approximately $7 million, making it the 12th largest holding in their portfolio.
• Maze Therapeutics stock is currently rated as a "Buy" by analysts, with a consensus price target of $25.60 following positive coverage from firms like Wedbush and HC Wainwright.
• Despite the recent investment and favorable analyst ratings, Maze Therapeutics has faced a decline in stock price, currently trading at $14.51, down 4.9%.

Harvard Management Co. Inc. purchased a new position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 637,528 shares of the company's stock, valued at approximately $7,019,000. Maze Therapeutics accounts for about 0.6% of Harvard Management Co. Inc.'s investment portfolio, making the stock its 12th biggest position. Harvard Management Co. Inc. owned about 1.46% of Maze Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Alphabet Inc. bought a new position in Maze Therapeutics in the 1st quarter worth approximately $26,561,000. New York State Common Retirement Fund bought a new position in Maze Therapeutics in the 1st quarter worth approximately $25,000. Bank of New York Mellon Corp bought a new position in Maze Therapeutics in the 1st quarter worth approximately $190,000. Bessemer Group Inc. bought a new position in Maze Therapeutics in the 1st quarter worth approximately $5,305,000. Finally, General Catalyst Group Management LLC bought a new position in Maze Therapeutics in the 1st quarter worth approximately $11,405,000.

Analyst Ratings Changes

MAZE has been the subject of a number of research reports. Wedbush initiated coverage on Maze Therapeutics in a research note on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price target for the company. HC Wainwright initiated coverage on Maze Therapeutics in a research note on Wednesday, July 23rd. They set a "buy" rating and a $34.00 price target for the company. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $25.60.

Maze Therapeutics Stock Down 1.4%

Shares of MAZE traded down $0.18 during trading hours on Friday, hitting $13.14. 72,288 shares of the company were exchanged, compared to its average volume of 155,301. The business's fifty day moving average is $13.90. Maze Therapeutics, Inc. has a one year low of $6.71 and a one year high of $19.19.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.39).

Maze Therapeutics Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.